Company & Partner News

XOMA raises up to $140M with Blue Owl Capital

“The Blue Owl financing provides us with significant non-dilutive capital to drive shareholder value through stock repurchases and additional royalty and milestone acquisitions,” stated Brad Sitko, Chief Investment Officer of XOMA.

Read More »

2023 Letter to Shareholders

Since joining the Company in January 2023 as Executive Chairman and interim CEO, I have come to better appreciate the opportunity presented by XOMA’s unique business model and seasoned team, and equally important, the optionality embedded within our growing royalty and milestone portfolio.

Read More »

2022 Letter to Stockholders

XOMA’s milestone and royalty aggregator business model began to demonstrate its potential in 2021 and the first few months of 2022. There are two key value driving elements to our strategy. One is to let the assets advance in the hands of the development partners, and as they experience success, the asset value to XOMA increases. The second is to acquire assets to continue growing our portfolio of potential milestone and royalty economics and further mitigate the risk associated with any single asset. The value of both elements were on display in 2021 and continue to show their impact in early 2022.

Read More »

2021 Year-end Letter to Shareholders

As we close out 2021 and look forward to all the possibilities 2022 will bring for XOMA, it seems appropriate to reflect on how much progress has been made by both our partners and our team. Today, within the XOMA portfolio of over 70 potential milestone and royalty assets, we have several programs that our partners have advanced into late stages of development.

Read More »

2021 Letter to Shareholders

For many of us, 2020 was a tale of two halves. The first half of 2020, COVID-19 hit and brought significant uncertainty to every aspect of our lives. We had to adapt and change how we lived and worked, unclear of when this uncertainty would end and when we could go back about our lives and our routines.

Read More »

2020 Letter to Shareholders

Everyone at XOMA hopes this letter finds you well. We collectively are experiencing a global event that few could have anticipated. It makes us remember what’s most important in life – our health, our families, our colleagues, and our friends. For our 10-person team, XOMA not only represents colleagues and friends, we also feel that XOMA is part of our family.

Read More »

CEO Letter – First Half 2019

In the first half of the year, there are have been some exciting developments for XOMA. Many of these events were communicated to the market by our license partners, which then provides us the opportunity to communicate in more detail with you. To this point in 2019, we have seen significant clinical advancement and received the first glimpses into the potential therapeutic value of several XOMA legacy partnered assets. And what we have seen is exciting!

Read More »